Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

NCT07651163 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Lisaftoclax

Interventions

DRUG: Lisaftoclax+daunorubicin+cytarabine
DRUG: Lisaftoclax+homoharringtonine+cytarabine+aclarubicin
DRUG: Lisaftoclax+azacitidine
DRUG: Lisaftoclax+ cytarabine
DRUG: Lisaftoclax+azacitidine or azacitidine

Sponsor

First Affiliated Hospital of Zhejiang University